Similar articles

• Suicidal risk in the treatment of outpatient schizophrenics with long-acting neuroleptics.

  Niturad A, Nicholschi-Oproiu L. Niturad A, et al. Agressologie. 1978;19(C):145-8. Agressologie. 1978. PMID: 35993 No abstract available.
• [Pharmaceutical characteristics of depot neuroleptics. Their use and efficacy in the psychiatric clinic].

  Mungiu OC, Chiriţă V, Boişteanu P, Mungiu A, Cosmovici N, Pirozynski T. Mungiu OC, et al. Rev Med Chir Soc Med Nat Iasi. 1988 Jan-Mar;92(1):43-7. Rev Med Chir Soc Med Nat Iasi. 1988. PMID: 2899341 Review. Romanian. No abstract available.
• Some aspects of the French contribution during the past ten years to the study and use of injectable long-acting neuroleptics.

  Lambert PA, Guinot G, Chabannes JP. Lambert PA, et al. Acta Psychiatr Belg. 1981 Mar-Apr;81(2):103-14. Acta Psychiatr Belg. 1981. PMID: 6117180 Review.
• [Depot preparations in psychiatry].

  Gunby B. Gunby B. Tidsskr Nor Laegeforen. 1974 Jan 30;94(3):176-7. Tidsskr Nor Laegeforen. 1974. PMID: 4150719 Norwegian. No abstract available.
• New drug development in France and French-speaking countries. Short and long acting neuroleptics.

  Deniker P, Ginestet D, Peron-Magnan P. Deniker P, et al. Dis Nerv Syst. 1974 Jul;35(7 Pt. 2):18-20. Dis Nerv Syst. 1974. PMID: 17894096 No abstract available.